|
|
|||
| RhD hemolytic disease results from transplacental passage of maternal antibodies against RhD antigens on fetal red blood cells. While administration of immune globulin to RhD-negative pregnant women has reduced the incidence of this disease, this prevention strategy is not effective for all patients. Information about fetal RhD genotype is useful for appropriate obstetric management of RhD-negative patients. Molecular genotyping offers the advantages of obtaining early information as well as avoidance of fetal blood sampling. Two homologous genes at the RhD locus on chromosome 1p36 encode the RhD antigen (the RhD gene) and the different RhC, Rhc, RhE and Rhe antigens (the RhCE gene). The genetic basis of the RhD blood type is the presence (RhD positive) or absence (RhD negative) of the RhD gene. Approximately 15% of Caucasians are RhD negative. For those RhD positive individuals, approximately 55% are heterozygous (RhD positive/RhD negative) and the remaining 45% are homozygous. Reasons for Referral:
Testing Methodology:PCR amplification of the RhD gene specific sequence with co-amplification of the RhCE sequence as an internal control to determine the presence or absence of RhD. Specimen Requirements:Direct fetal
specimen: amniotic fluid, 10 cc in a
sterile container. Turnaround Time:3 weeks CPT Codes and Prices:83900, 83901x2, 83894x2, 83890, 83912 Shipping InformationForms: >> DNA
Requisition Test Codes:
Index: 6052 |